Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development. At a meeting with the investment community today, Merck (MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term. “Over the last five years, we have revitalized our focus on research in order to invent, develop and commercialize valuable and innovative medicines and vaccines that address many of the world’s most pressing health challenges.”. The company expects to continue its momentum and deliver strong revenue growth every year in the next five years, including 2023 – the year of greatest anticipated impact of the JANUVIA LOE – driven by demand for its portfolio of innovative products across oncology, vaccines, hospital acute care and animal health.